Omnicell (OMCL) Q2 2026: $0.94 EPS Doubles Estimates on Tariff Refund
As seen on the 24/7 Wall St. homepage on July 30, 2026.
Omnicell doubled earnings expectations with $0.94 EPS versus a $0.47 estimate, powered by a $15 million tariff refund and resilient demand for pharmacy automation that lifted non-GAAP EBITDA margin to 21.5% from 13.2% year ago. The company raised full-year profit guidance to $2.15 to $2.30 EPS but trimmed annual recurring revenue guidance as certain growth opportunities develop more slowly than expected.
Continue ReadingShow less
Omnicell's Q2 2026 result was its strongest earnings beat in at least two years, with reported EPS of $0.94 coming in more than double the $0.47 consensus estimate. A $15 million tariff refund provided a meaningful lift, but the quarter also reflected genuine operating momentum — non-GAAP EBITDA margin expanded to 21.5%, up sharply from 13.2% in the same quarter a year ago, signaling that the pharmacy automation business is generating significantly more profit on each revenue dollar.
On the top line, revenue came in at $312.2 million, edging past the $310.2 million estimate. The beat was modest compared to the earnings upside, but it underscores that demand for Omnicell's core automation products remained resilient. The company has now beaten EPS estimates in seven of the past eight quarters, with Q4 2025 being the lone miss, when it reported $0.40 against a $0.50 estimate.
Sponsored
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
Looking ahead, management raised full-year EPS guidance to a range of $2.15 to $2.30, reflecting confidence in the profitability outlook. However, it trimmed annual recurring revenue guidance, acknowledging that some growth opportunities are developing more slowly than previously expected — a nuance investors will want to watch as the company navigates its transition toward a subscription-driven model.
Mentioned: OMCL